Harmony Biosciences Holdings, Inc.
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
HRMY$33.78+2.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| | | | | | | |
|---|---|---|---|---|---|---|
| · · December 31, · · December 31, | ||||||
| · · 2025 · · 2024 | ||||||
| ASSETS · · · · | ||||||
| CURRENT ASSETS: · · · · | ||||||
| Cash and cash equivalents | | $752,502 | | $453,001 | ||
| Investments, short-term | | | 22,838 | | | 14,185 |
| Trade receivables, net | | 96,787 | | 83,033 | ||
| Inventory, net | | 5,357 | | 7,198 | ||
| Prepaid expenses | | 16,014 | | 13,714 | ||
| Other current assets | | 13,516 | | 8,121 | ||
| Total current assets | | 907,014 | | 579,252 | ||
| NONCURRENT ASSETS: | | | | | ||
| Investments, long-term | | | 107,127 | | | 108,874 |
| Intangible assets, net | | 89,418 | | 113,263 | ||
| Deferred tax asset | | | 149,699 | | | 190,398 |
| Other noncurrent assets | | 18,373 | | 7,413 | ||
| Total noncurrent assets | | 364,617 | | 419,948 | ||
| TOTAL ASSETS | | $1,271,631 | | $999,200 | ||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | | | | | ||
| CURRENT LIABILITIES: | | | | | ||
| Trade payables | | $17,693 | | $13,744 | ||
| Accrued compensation | | 18,443 | | 18,776 | ||
| Accrued expenses | | 191,039 | | 120,640 | ||
| Current portion of long-term debt | | | 20,000 | | | 16,250 |
| Other current liabilities | | 4,957 | | 5,672 | ||
| Total current liabilities | | 252,132 | | 175,082 | ||
| NONCURRENT LIABILITIES: | | | | | ||
| Long-term debt, net | | 143,663 | | 163,016 | ||
| Other noncurrent liabilities | | 5,618 | | 1,947 | ||
| Total noncurrent liabilities | | 149,281 | | 164,963 | ||
| TOTAL LIABILITIES | | 401,413 | | 340,045 | ||
| COMMITMENTS AND CONTINGENCIES (Note 13) | | | | | ||
| STOCKHOLDERS’ EQUITY: | | | | | ||
| Common stock—$0.00001 par value; 500,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively; 57,726,170 and 57,144,887 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | | 1 | | 1 | ||
| Additional paid in capital | | 708,968 | | 656,872 | ||
| Accumulated other comprehensive income | | | 346 | | | 66 |
| Retained earnings | | 160,903 | | 2,216 | ||
| TOTAL STOCKHOLDERS’ EQUITY | | 870,218 | | 659,155 | ||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | | $1,271,631 | | $999,200 | ||
The accompanying notes are an integral part of the consolidated financial statements
HARMONY BIOSCIENCES HOLDINGS, INC. AND SUBSIDIARIES
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.